New research from Weill Cornell Medicine shows that weight loss achieved using injectable obesity drugs tirzepatide or semaglutide can be effectively maintained by switching to daily oral orforglipron.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
Most weight loss achieved using injectable obesity drugs can be maintained by switching to orforglipron, study shows
74.7% % Weight loss maintained
43.7% % Patients maintaining ≥80% weight loss
16.8% % Mean body weight reduction
GLP-1 Receptor Agonist Drug type